Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj Precision Oncology of the validation study for its Latitude tissue-free ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal ...
Natera, Inc. (NASDAQ:NTRA) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts. On March 12, ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS) ...
Zacks Investment Research on MSN
NTRA debuts Zenith Genomics next-gen sequencing test for rare diseases
Natera NTRA announced the commercial launch of Zenith genomics, a next-generation whole genome sequencing assay designed to ...
Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter for the “Carillon Eagle Mid Cap Growth Fund”. A copy of the letter can be downloaded here.
Jury awards Natera more than $83 mln in lost profits and $12 mln in royalties Natera accused CareDx's rival kidney-transplant tests of infringing patents Sign up here. CareDx said in a court filing ...
Genetic testing company Natera (NASDAQ:NTRA). will be reporting results this Thursday afternoon. Here’s what investors should know. Natera beat analysts’ revenue expectations last quarter, reporting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results